-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Alnylam delivered exceptional Q1 2026 results, achieving a historic milestone of over $1B in quarterly product revenues for the first time in its 23-year history. The company reported non-GAAP EPS of $2.05 vs. $0.29 in the prior year, significantly ahead of the $1.47 consensus, while total revenues reached $1,167M (+96% Y/Y), driven by outstanding net product revenue performance of $1,036M (+121% Y/Y). The TTR franchise continued its remarkable growth trajectory, generating $910M (+153% Y/Y), with AMVUTTRA contributing $890M (+187% Y/Y) as the therapy maintained exceptional commercial momentum one year after its U.S. launch for ATTR-CM. The company reiterated its 2026 financial guidance, projecting total net product revenues of $4.9B-$5.3B and TTR net product revenues of $4.4B-$4.7B. Management highlighted significant pipeline progress, including faster-than-anticipated enrollment in the TRITON-CM Phase 3 study of nucresiran, with multiple clinical readouts expected in 2H 2026.